Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Net Income
Bottom-line profit after all expenses, interest, and taxes.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income remains negative
Q4 FY2025 net income was -$15.11M, compared with -$8.91M a year earlier.
Context
- Net income amounted to 86687.5% of revenue in FY2025, up 86627.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$55.3M (+0.3%) for the fiscal year ending Dec 2026, a step up from the -255.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$15.11M— QoQ
- Last fiscal yearDec 2025
- -$55.48M-255.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -69.6% | — | — |
| 1 year | -255.0% | +0.3% | +255.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (55.48M) USD
- Year-over-year change
- -255.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (55.48M) | -255.0% |
| FY2024 | 2024-12-31 | (15.63M) | +74.8% |
| FY2023 | 2023-12-31 | (62.11M) | +47.4% |
| FY2022 | 2022-12-31 | (118.09M) | +41.6% |
| FY2021 | 2021-12-31 | (202.27M) | — |
Net Income vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -255.0% is the lowest of 9, against a peer median of +3.6%.
- Net income amounts to 86687.5% of revenue for CNTB, versus a peer median of 2663.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$24.17M USD | +3.2% | — | 339.3% | |
| LTM Mar 2026 | -$40.23M USD | -45.6% | — | — | |
| LTM Mar 2026 | -€42.91M EUR | +4.0% | — | 146303.9% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.1M USD | +38.9% | — | — |
IMAImageneBio Inc | LTM Mar 2026 | -$45.07M USD | -8.1% | — | — |
| LTM Mar 2026 | -$49.87M USD | +29.4% | — | 4987.4% | |
| FY2025 | -$55.48M USD | -255.0% | — | 86687.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$87.07M USD | -34.3% | — | — |
| LTM Mar 2026 | -$153.6M USD | +37.4% | — | 154.2% | |
| Peer median (excluding CNTB) | — | +3.6% | — | 2663.4% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.